Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$319.71
-4.26-1.31%
At close: -
$319.71
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
United Therapeutics Analyst Ratings and Price Targets | NASDAQ:UTHR | Benzinga
United Therapeutics Corp has a consensus price target of $377.56 based on the ratings of 16 analysts. The high is $600 issued by Oppenheimer on October 31, 2024. The low is $294 issued by JP Morgan on November 2, 2023. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, HC Wainwright & Co., and JP Morgan on June 2, 2025, May 5, 2025, and May 1, 2025, respectively. With an average price target of $393.33 between Cantor Fitzgerald, HC Wainwright & Co., and JP Morgan, there's an implied 23.03% upside for United Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
HC Wainwright & Co.
JP Morgan
Morgan Stanley
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for United Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/02/2025 | Buy Now | 26.68% | Cantor Fitzgerald | Olivia Brayer54% | → $405 | Initiates | → Overweight | Get Alert |
| 05/05/2025 | Buy Now | 32.93% | HC Wainwright & Co. | Andrew Fein57% | $425 → $425 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2025 | Buy Now | 9.47% | JP Morgan | Jessica Fye70% | $355 → $350 | Maintains | Overweight | Get Alert |
| 05/01/2025 | Buy Now | 8.85% | Morgan Stanley | Terence Flynn5% | $346 → $348 | Maintains | Equal-Weight | Get Alert |
| 04/25/2025 | Buy Now | -1.79% | Wells Fargo | Tiago Fauth47% | $395 → $314 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 04/21/2025 | Buy Now | 11.04% | JP Morgan | Jessica Fye70% | $357 → $355 | Maintains | Overweight | Get Alert |
| 04/21/2025 | Buy Now | -1.79% | B of A Securities | Greg Harrison49% | $314 → $314 | Upgrade | Underperform → Neutral | Get Alert |
| 02/27/2025 | Buy Now | 32.93% | HC Wainwright & Co. | Andrew Fein57% | $425 → $425 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2025 | Buy Now | 48.57% | UBS | Ashwani Verma49% | $415 → $475 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | -5.54% | Goldman Sachs | Chris Shibutani57% | $243 → $302 | Maintains | Neutral | Get Alert |
| 10/31/2024 | Buy Now | 7.6% | Ladenburg Thalmann | Matthew Kaplan65% | $319 → $344 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 87.67% | Oppenheimer | Hartaj Singh45% | $575 → $600 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 25.11% | Argus Research | Jasper Hellweg68% | $360 → $400 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 32.93% | HC Wainwright & Co. | Andrew Fein57% | $400 → $425 | Maintains | Buy | Get Alert |
| 10/21/2024 | Buy Now | 25.11% | TD Cowen | Joseph Thome27% | $350 → $400 | Maintains | Buy | Get Alert |
| 09/23/2024 | Buy Now | 35.12% | Jefferies | Eun Yang8% | $315 → $432 | Maintains | Buy | Get Alert |
| 08/28/2024 | Buy Now | 79.85% | Oppenheimer | Hartaj Singh45% | $400 → $575 | Maintains | Outperform | Get Alert |
| 08/20/2024 | Buy Now | 18.86% | Wells Fargo | Tiago Fauth47% | $350 → $380 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 25.11% | HC Wainwright & Co. | Andrew Fein57% | $400 → $400 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2024 | Buy Now | -12.42% | B of A Securities | Greg Harrison49% | $303 → $280 | Maintains | Underperform | Get Alert |
| 07/25/2024 | Buy Now | 25.11% | HC Wainwright & Co. | Andrew Fein57% | $300 → $400 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 9.47% | TD Cowen | Joseph Thome27% | $270 → $350 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | 0.4% | Morgan Stanley | Terence Flynn5% | $310 → $321 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 07/08/2024 | Buy Now | 15.73% | UBS | Ashwani Verma49% | $300 → $370 | Maintains | Buy | Get Alert |
| 06/12/2024 | Buy Now | 9.47% | Wells Fargo | Tiago Fauth47% | $325 → $350 | Maintains | Overweight | Get Alert |
| 05/21/2024 | Buy Now | -6.16% | JP Morgan | Jessica Fye70% | $280 → $300 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | -24.93% | Goldman Sachs | Chris Shibutani57% | $218 → $240 | Maintains | Neutral | Get Alert |
| 05/02/2024 | Buy Now | -6.16% | HC Wainwright & Co. | Andrew Fein57% | $300 → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 25.11% | Oppenheimer | Hartaj Singh45% | $375 → $400 | Maintains | Outperform | Get Alert |
| 03/07/2024 | Buy Now | 1.65% | Wells Fargo | Tiago Fauth47% | $309 → $325 | Maintains | Overweight | Get Alert |
| 02/22/2024 | Buy Now | -3.66% | Wedbush | Liana Moussatos74% | $308 → $308 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | -6.16% | HC Wainwright & Co. | Andrew Fein57% | $300 → $300 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2024 | Buy Now | -32.75% | Goldman Sachs | Chris Shibutani57% | $213 → $215 | Upgrade | Sell → Neutral | Get Alert |
| 02/05/2024 | Buy Now | 3.22% | Leerink Partners | Roanna Ruiz37% | → $330 | Initiates | → Outperform | Get Alert |
| 11/02/2023 | Buy Now | -8.04% | JP Morgan | Jessica Fung39% | $290 → $294 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | -1.79% | Morgan Stanley | Terence Flynn5% | $318 → $314 | Maintains | Overweight | Get Alert |
| 11/02/2023 | Buy Now | -3.66% | Wedbush | Liana Moussatos74% | $307 → $308 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | -0.53% | Morgan Stanley | Terence Flynn5% | $316 → $318 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | -16.17% | Ladenburg Thalmann | Matthew Kaplan65% | $256 → $268 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -3.98% | Wedbush | Liana Moussatos74% | $305 → $307 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | -6.16% | HC Wainwright & Co. | Andrew Fein57% | → $300 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | Buy Now | -19.93% | Ladenburg Thalmann | Matthew Kaplan65% | $285 → $256 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | -12.42% | Argus Research | Jasper Hellweg68% | $300 → $280 | Maintains | Buy | Get Alert |
| 04/10/2023 | Buy Now | -3.04% | UBS | Ashwani Verma49% | $330 → $310 | Maintains | Buy | Get Alert |
| 04/10/2023 | Buy Now | -1.16% | Morgan Stanley | Terence Flynn5% | $320 → $316 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -12.42% | JP Morgan | Jessica Fung39% | $265 → $280 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | 0.09% | Morgan Stanley | Terence Flynn5% | $330 → $320 | Maintains | Overweight | Get Alert |
| 02/23/2023 | Buy Now | -6.16% | HC Wainwright & Co. | Andrew Fein57% | → $300 | Reiterates | → Buy | Get Alert |
| 01/11/2023 | Buy Now | -6.16% | Argus Research | Jasper Hellweg68% | $250 → $300 | Maintains | Buy | Get Alert |
| 12/06/2022 | Buy Now | 3.22% | Morgan Stanley | Terence Flynn5% | $322 → $330 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 0.09% | UBS | Ashwani Verma49% | → $320 | Initiates | → Buy | Get Alert |
| 12/05/2022 | Buy Now | -28.06% | Goldman Sachs | Chris Shibutani57% | → $230 | Initiates | → Sell | Get Alert |
| 11/03/2022 | Buy Now | -17.11% | JP Morgan | Jessica Fye70% | $240 → $265 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 0.72% | Morgan Stanley | Terence Flynn5% | $288 → $322 | Maintains | Overweight | Get Alert |
| 11/03/2022 | Buy Now | 17.29% | Oppenheimer | Hartaj Singh45% | $325 → $375 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | -6.16% | HC Wainwright & Co. | Andrew Fein57% | $255 → $300 | Maintains | Buy | Get Alert |
| 10/11/2022 | Buy Now | -9.92% | Morgan Stanley | Terence Flynn5% | → $288 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for United Therapeutics (UTHR) stock?
The latest price target for United Therapeutics (NASDAQ:UTHR) was reported by Cantor Fitzgerald on June 2, 2025. The analyst firm set a price target for $405.00 expecting UTHR to rise to within 12 months (a possible 26.68% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for United Therapeutics (UTHR)?
The latest analyst rating for United Therapeutics (NASDAQ:UTHR) was provided by Cantor Fitzgerald, and United Therapeutics initiated their overweight rating.
When was the last upgrade for United Therapeutics (UTHR)?
The last upgrade for United Therapeutics Corp happened on April 21, 2025 when B of A Securities raised their price target to $314. B of A Securities previously had an underperform for United Therapeutics Corp.
When was the last downgrade for United Therapeutics (UTHR)?
The last downgrade for United Therapeutics Corp happened on April 25, 2025 when Wells Fargo changed their price target from $395 to $314 for United Therapeutics Corp.
When is the next analyst rating going to be posted or updated for United Therapeutics (UTHR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on June 2, 2025 so you should expect the next rating to be made available sometime around June 2, 2026.
Is the Analyst Rating United Therapeutics (UTHR) correct?
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a initiated with a price target of $0.00 to $405.00. The current price United Therapeutics (UTHR) is trading at is $319.71, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
